An Open-Label, Multicenter, Phase Ia/b Study Evaluating the Safety and Pharmacokinetics of RO7851624 in Patients With Relapsed/Refractory Multiple Myeloma
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1
SUMMARY
This study will evaluate safety, pharmacokinetics (PK), clinical activity and pharmacodynamics (PD) of RO7851624 in participants with RRMM who are triple-class exposed (treated with proteasome inhibitors \[PIs\], immunomodulators \[IMiDs\], and anti-cluster of differentiation 38 \[anti-CD38\] monoclonal antibodies), and have limited remaining standard treatment options due to refractoriness, intolerance, or multiple prior therapies.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
• Life expectancy of at least 12 weeks.
• Diagnosis of multiple myeloma per International Myeloma Working Group (IMWG) criteria.
• Measurable disease.
Locations
Other Locations
Australia
Peter MacCallum Cancer Center
RECRUITING
Parkville
Contact Information
Primary
Reference Study ID Number: GO46140 https://forpatients.roche.com/ No attachments to email below.
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. and Canada)
Backup
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Time Frame
Start Date: 2026-06-23
Estimated Completion Date: 2031-10-01
Participants
Target number of participants: 160
Treatments
Experimental: RO7851624
Participants will receive RO7851624 in a dose escalation stage followed by a dose expansion stage.
Related Therapeutic Areas
Sponsors
Leads: Genentech, Inc.